Health ministry decides against including Itolizumab in clinical management protocols for COVID-19

The permission to market the drug was granted for the treatment of cytokine release syndrome in 'moderate' to 'severe' Acute Respiratory Distress Syndrome patients due to COVID-19.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/39wPOZ2
via IFTTT